02:15 , Dec 16, 2017 |  BioCentury  |  Product Development

Assessing the BCMA scene

Differences in patient populations and a dearth of clinical outcome data mean it’s too soon to declare bluebird bio Inc.’s anti-BCMA chimeric antigen receptor therapy the leader of the pack of CARs that presented clinical...
04:21 , Dec 9, 2017 |  BioCentury  |  Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
23:52 , Nov 6, 2017 |  BC Extra  |  Preclinical News

Team identifies new target for MM CAR T therapy

In a paper published in Nature Medicine, researchers at Osaka University and colleagues identified activated integrin beta(7) as a new target for a chimeric antigen receptor (CAR) T cell therapy for multiple myeloma, demonstrating that...
20:06 , Oct 24, 2017 |  BC Innovations  |  Distillery Techniques

Drug delivery; drug platforms

TECHNOLOGY: Nanoparticles; cell therapy Nanoparticles loaded with mRNA could be used for ex vivo programming of patient-derived CAR T cells as cancer therapies. The nanoparticles consist of a biodegradable poly(β-amino ester) polymer core loaded with synthetic...
22:41 , Oct 16, 2017 |  BC Extra  |  Preclinical News

Cytokines could predict risk of CAR T neurotoxicities

In a paper published in Cancer Discovery, researchers at the Fred Hutchinson Cancer Research Center and colleagues found that the IL-6 and monocyte chemoattractant protein-1 (MCP-1; CCL2) cytokines could act as early biomarkers along with...
18:47 , Mar 17, 2017 |  BioCentury  |  Emerging Company Profile

B-ing persistent

Aleta Biotherapeutics Inc. is extending the use of CD19-targeting CAR T cells by coating non-B cell tumors with the antigen. President and CSO Paul Rennert told BioCentury the key to effective CAR T cell therapies is...
03:48 , Dec 10, 2016 |  BioCentury  |  Product Development

Rules of the road

Investigators and companies have long been devising strategies to mitigate or preempt toxicities from CAR T cell therapies without compromising efficacy. Now, data presented at the American Society of Hematology meeting suggest strategies to prevent...
07:00 , Oct 6, 2016 |  BC Innovations  |  Product R&D

Local sensitivity

With a toolbox full of synthetic protein modules and a deal with Kite Pharma Inc. under its belt, Cell Design Labs Inc. is aiming to advance the next generation in cell-based therapies with a "smart"...
07:00 , Sep 15, 2016 |  BC Innovations  |  Emerging Company Profile

Synthetic CAR controls

An ongoing challenge with chimeric antigen receptor (CAR) T cells is controlling expression of the engineered CARs to prevent cytotoxic side effects while still promoting efficacy. Chimera Bioengineering is applying synthetic biology to create a...
07:00 , Jul 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Mucin 1 (MUC1; CD227)

Cancer INDICATION: Cancer Mouse studies suggest chimeric antigen receptor (CAR) T cells targeting a tumor-specific glycoform of MUC1 could help treat cancers that express the glycoform. Primary human T cells were engineered to express a CAR composed...